Genomic Health-backed Invitae, which is developing a new genetic testing system, would raise more than $80m if it floats at the top of its range.
Invitae Corporation, the US-based genetic testing technology provider backed by diagnostic testing company Genomic Health, set the range for its initial public offering yesterday between $13 and $15 per share.
The company plans to issue 5.35 million shares on the New York Stock Exchange, which will net it approximately $80.3m if it floats at the top of its range.
Spun out from Genomic in 2012, Invitae is developing a system that aggregates most of the world’s genetic tests into…
